GLP-1-RA or SGLT-2 inhibitors have positively impacted vascular outcomes in patients with DM II and CVD, warranting investigation in post-stroke cohorts.12 Currently, we identified no planned phase III studies for GLP-1-RA or SGLT-2 inhibitors in this setting. Here, SLC5A2 is linked to stroke disorder.